{"nctId":"NCT01309243","briefTitle":"Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","startDateStruct":{"date":"2011-02"},"conditions":["HIV-1 Infection"],"count":799,"armGroups":[{"label":"FTC/RPV/TDF","type":"EXPERIMENTAL","interventionNames":["Drug: FTC/RPV/TDF"]},{"label":"EFV/FTC/TDF","type":"EXPERIMENTAL","interventionNames":["Drug: EFV/FTC/TDF"]}],"interventions":[{"name":"FTC/RPV/TDF","otherNames":["Complera®","Eviplera®"]},{"name":"EFV/FTC/TDF","otherNames":["Atripla®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ability to understand and sign a written informed consent form\n* Plasma HIV-1 RNA levels ≥ 2,500 copies/mL at screening\n* No prior use of any approved or experimental anti-HIV drug for any length of time\n* Screening genotype report showing sensitivity to EFV, FTC, TDF, and lack of the RPV mutations K101E/P, E138A/G/K/Q/R, Y181C/I/V, and H221Y\n* Normal ECG\n* Hepatic transaminases (alanine aminotransferase \\[ALT\\] and aspartate aminotransferase \\[AST\\]) ≤ 5 x the upper limit of the normal range (ULN)\n* Total bilirubin ≤ 1.5 mg/dL, or normal direct bilirubin\n* Adequate hematologic function\n* Serum amylase ≤ 5 x ULN (participants with serum amylase \\> 5 x ULN remained eligible if serum lipase was ≤ 5 x ULN)\n* Adequate renal function\n* Males and Females of childbearing potential must have agreed to utilize highly effective contraception methods (two separate forms of contraception, one of which must be an effective barrier method, or be non-heterosexually active, practice sexual abstinence or have a vasectomized partner) from screening throughout the duration of study period and for 12 weeks following the last dose of study drug.\n* Adult (≥ 18 years) males or non-pregnant females\n\nExclusion Criteria:\n\n* A new AIDS-defining condition diagnosed within the 30 days prior to screening\n* Females who were breastfeeding\n* Positive serum pregnancy test (female of childbearing potential)\n* Proven or suspected acute hepatitis in the 30 days prior to study entry\n* Subjects receiving drug treatment for hepatitis C, or subjects who were anticipated to receive treatment for hepatitis C during the course of the study\n* Subjects experiencing decompensated cirrhosis\n* Had an implanted defibrillator or pacemaker\n* Current alcohol or substance abuse\n* A history of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma\n* Active, serious infections requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline\n* Receiving ongoing therapy or anticipated to need to initiate drugs or herbal/natural supplements during the study that are contraindicated or not recommended for use, including drugs not to be used with FTC, EFV, RPV, or TDF; or subjects with known allergies to the excipients of the FTC/RPV/TDF or EFV/FTC/TDF single-tablet regimens\n* Participation in any other clinical trial without prior approval from the sponsor was prohibited while participating in this trial.\n* Had been treated with immunosuppressant therapies or chemotherapeutic agents within 3 months of study screening, or expected to receive these agents or systemic steroids for immunosuppression during the study (eg, corticosteroids, immunoglobulins, and other immune-based or cytokine-based therapies)\n* Had any other clinical condition or prior therapy that, in the opinion of the Investigator, would have made the participant unsuitable for the study or unable to comply with the dosing requirements","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 48 was analyzed using the US FDA snapshot algorithm.\n\nThe snapshot algorithm defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.8","spread":null},{"groupId":"OG001","value":"81.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96","description":"The percentage of participants with HIV-1 RNA \\< 50 copies/mL at Week 96 was analyzed using the US FDA snapshot algorithm.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.9","spread":null},{"groupId":"OG001","value":"72.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"200","spread":"158.6"},{"groupId":"OG001","value":"191","spread":"144.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count at Week 96","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"278","spread":"186.6"},{"groupId":"OG001","value":"259","spread":"191.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Total Cholesterol at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"28.1"},{"groupId":"OG001","value":"22","spread":"31.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting High-density Lipoprotein (HDL) Cholesterol at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"8.7"},{"groupId":"OG001","value":"8","spread":"10.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Low-density Lipoprotein (LDL) Cholesterol at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"24.4"},{"groupId":"OG001","value":"14","spread":"28.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Triglycerides at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8","spread":"68.9"},{"groupId":"OG001","value":"8","spread":"103.0"}]}]}]},{"type":"SECONDARY","title":"Development of HIV-1 Drug Resistance Through Week 96, All Participants","description":"Participants who experienced either suboptimal virologic response or virologic rebound were considered to have virologic failure and were analyzed for resistance. Suboptimal virologic response was assessed at Week 8 and was defined as having HIV-1 RNA ≥ 50 copies/mL and \\< 1-log10 reduction from baseline at the Week 8 visit, which was confirmed at the subsequent visit. Virologic rebound was defined as having 2 consecutive visits with HIV-1 RNA ≥ 400 copies/mL after achieving HIV-1 RNA \\< 50 copies/mL, or as having 2 consecutive visits with \\> 1 log10 increase in HIV-1 RNA from their nadir. In addition, subjects who were on study drugs, had not been analyzed previously, and who had HIV-1 RNA ≥ 400 copies/mL at Week 48, Week 96, or their last visit (at or after Week 8) were also analyzed for resistance at their last visit. Subsequent to the first resistance testing, subjects experiencing repeated confirmed virologic failure were assessed for resistance retesting on a case-by-case basis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Development of HIV-1 Drug Resistance Through Week 96, Participants With Viral Resistance","description":"Resistance Analysis Set: participants with either suboptimal virologic response or virologic rebound were considered to have virologic failure and were analyzed. Suboptimal virologic response was assessed at Week 8 and was defined as having HIV-1 RNA ≥ 50 copies/mL and \\< 1-log10 reduction from baseline at the Week 8 visit, which was confirmed at the subsequent visit. Virologic rebound was defined as having 2 consecutive visits with HIV-1 RNA ≥ 400 copies/mL after achieving HIV-1 RNA \\< 50 copies/mL, or as having 2 consecutive visits with \\> 1 log10 increase in HIV-1 RNA from their nadir. In addition, subjects who were on study drugs, had not been analyzed previously, and who had HIV-1 RNA ≥ 400 copies/mL at Week 48, Week 96, or their last visit (at or after Week 8) were also analyzed for resistance at their last visit. Subsequent to the first resistance testing, subjects experiencing repeated confirmed virologic failure were assessed for resistance retesting on a case-by-case basis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":394},"commonTop":["Diarrhoea","Nausea","Upper respiratory tract infection","Abnormal dreams","Dizziness"]}}}